about
Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular ViewHumanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modellingCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinLyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.Preparation and characterization of recombinant protein ScFv(CD11c)-TRP2 for tumor therapy from inclusion bodies in Escherichia coli.Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.Preparation and Characterization of Paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody.Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells.Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab.Development and characterization of a novel anti-IgE monoclonal antibody.Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabThe protein-protein interface evolution acts in a similar way to antibody affinity maturation.Novel dual-control poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release.Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expressionPhase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.Identification of a novel functional domain of ricin responsible for its potent toxicity.Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allograftsTolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Acid-induced aggregation propensity of nivolumab is dependent on the Fc.Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer.Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.Development and characterization of a fully functional small anti-HER2 antibody.Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.Genetically targeted T cells eradicate established breast cancer in syngeneic mice.Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection.Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.A chimeric SM5-1 antibody inhibits hepatocellular carcinoma cell growth and induces caspase-dependent apoptosis.Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.Functional and stable expression of recombinant human FOXP3 in bacterial cells and development of antigen-specific monoclonal antibodies.Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody.
P50
Q27679553-A99ADAFD-A367-4DE7-A325-55A83B68CFB7Q28277157-70D10C1D-7ACA-4387-937B-081A88484590Q28537820-AA0055BB-12F5-4D24-9A65-E0EBFBC69E5CQ30976158-7B77F65F-C210-4D7D-B83D-19A2B4D5EE4CQ33259687-6D7E4373-A70F-4F26-8947-3D403478BFDBQ33278735-90DDBD85-94C6-4C6A-8882-47FE319F669CQ33302223-7642639F-8C0F-444C-A08F-E70ED3FB59D2Q33346360-67BDF953-1EAB-4755-A88C-F1C03F60ADC3Q33362984-9C82883E-739F-4143-9DC3-6F47D26B4809Q33556171-C9031B8A-3626-4B30-A027-40D2EA093303Q33573605-476AA5B7-01B0-4934-B7B6-203DF563F462Q33662167-27F06847-B0D3-4923-B935-85AA6FA5733DQ34183165-DAAF0ABC-F383-463B-B717-858F73E3D48BQ34483555-8AFA5E26-3AA1-4BBF-9070-9560EE5083F1Q34570074-3088A616-D43D-4384-82DD-B48CC21C0722Q34752125-45B8E0DD-DF67-4B2A-94E4-832061319524Q35232365-14914FF4-FD8C-4E58-8264-7D0CE0E75EBAQ35918874-5F5B1F09-DBFB-4E16-BFB4-179DF958B42FQ36213066-374DE3D6-E1FF-4E4B-8B1A-FE8B523BF008Q37138420-1F1A13BC-8F41-4493-902F-10727EC92C85Q37141601-8A762B27-03BB-4B08-88CE-F29677359E1EQ37273477-F672B623-5CE1-447A-944C-0FE123E3DE36Q39092788-8564857D-4C71-4B50-9672-ADD8C24745FAQ39308438-1F4A7F5B-8B2C-4777-BFF0-725CADC1B7A9Q39357142-7ED9139C-3928-468A-A468-A1F268FF6FCFQ39597383-2BB4F279-19CD-42DB-8D58-D98047FD9331Q39733175-8B711D3D-8EB7-4AB1-9679-9F986BA1F91EQ39782019-F7208F61-2BB9-42A0-9A25-CC652139B9A6Q39787467-3936E55B-847C-4430-83F5-D865CA73702FQ39810957-86381269-5C25-4DA4-83D5-F50E0D372066Q39827951-F1D1B183-2E62-4138-82E0-952283E58B29Q39888332-F7611ED2-26C6-4CF8-BA69-719B933A2392Q39962261-32E06D21-2716-4407-87B0-6180D1320E3EQ39981867-D7DECA77-E58F-422F-BA53-912D50CCDCCCQ39982179-B23EE3B2-6AE7-4D56-82BF-DB34B3721D81Q39996218-1102FCDB-7C77-4B5E-AF98-125BE18E2B95Q40062899-0E881877-2916-43CE-9CC9-CE2B59AFCD28Q40064751-E4523E5B-0D0A-4798-B526-2D6DAB493247Q40087008-BEE95F68-EDBB-4A5A-8BDA-6F6D280BA667Q40142517-F2AC81A9-D34A-4666-9310-0DFF555569AE
P50
name
Weizhu Qian
@en
Weizhu Qian
@nl
type
label
Weizhu Qian
@en
Weizhu Qian
@nl
prefLabel
Weizhu Qian
@en
Weizhu Qian
@nl